Lomefloxacin

Summary

Lomefloxacin (CHEMBL561) is an approved small-molecule antimicrobial agent (ATC J01MA07); indicated across 3 conditions including bacterial infectious disease and eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01MA07 (+1 more)
• Indications: 3 conditions
• Chemistry: 351.35 Da · C17H19F2N3O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL561
Name	Lomefloxacin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3948
ChEBI	CHEBI:116278
ATC	J01MA07, S01AE04
Molecular formula	C17H19F2N3O3
Molecular weight	351.35
InChIKey	ZEKZLJVOYLTDKK-UHFFFAOYSA-N

SMILES: CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O

IUPAC name: 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid

ChEBI definition: A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.

Pharmacological roles (ChEBI): antimicrobial agent, photosensitizing agent, antitubercular agent.

Also known as: Lomefloxacin, Lomefloxacine, Lomefloxacino, Okacyn, SC-47111A, lomefloxacin, lemofloxacin, SID90340951, LOMEFLOXACIN, LOMEFLOXACINE, SID174007186

Parent form; salt/anhydrous children: CHEMBL1728, CHEMBL2106827, CHEMBL3765217

Patent coverage: 6,126 distinct patent families (22,132 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 21,813 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
eye infectious disorder	4	MONDO:0043885	EFO:1001888
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).